The large remaining ATM capacity relative to market cap creates a persistent overhang that may cap upside and pressure the stock. Monitor daily ADS volume and any subsequent 424B5 filings for actual ATM sales. The reduction from $100M to $80M is a modest positive signal but does not eliminate the dilution risk.
Price Chart
Executive Summary
Kazia Therapeutics filed a 6-K and a 424B5 prospectus supplement on August 28, 2026, reducing the maximum aggregate offering price of ADSs available under its existing ATM facility with Leerink Partners from $100M to $80M. As of the filing, the company had already sold 510,000 ADSs for approximately $5.1M under the facility. The reduction in the ATM ceiling is a modest administrative update, but the ongoing ATM facility represents a persistent overhang that could dilute existing shareholders at the current $16.90 ADS price, particularly given the company's $193M market cap and the large remaining capacity of ~$74.9M.
Key Facts
- Kazia reduced its ATM facility maximum from $100M to $80M.
- 510,000 ADSs have been sold for ~$5.1M under the facility to date.
- The remaining capacity under the ATM is up to ~$74.9M.
- ADSs trade on Nasdaq at $16.90 as of August 27, 2026.
- The ATM facility is with Leerink Partners LLC as sales agent.
- The company has a market cap of ~$193M, making the remaining ATM capacity ~39% of market cap.
- The 6-K and 424B5 were filed on the same day, August 28, 2026.
Financial Impact
Remaining ATM capacity of up to ~$74.9M represents ~39% of current market cap, creating significant potential dilution.
Risk Factors
- Potential dilution from future ATM sales of up to ~$74.9M in ADSs.
- ATM overhang may suppress stock price and limit upside.
- No operational or pipeline catalysts disclosed in this filing to offset dilution concerns.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (KZIA) — Batch item 1 | 0001213900-26-094603 |
| Document: 0001213900-26-094603-index-headers.html | 0001213900-26-094603 |
| Document: 0001213900-26-094603-index.html | 0001213900-26-094600 |
| Document: 0001213900-26-094603.txt | 0001213900-26-094603 |
| 6-K Filing (KZIA) — Batch item 5 | 0001213900-26-094603 |
| Document: 0001213900-26-094603-index-headers.html | 0001213900-26-094603 |
| Document: 0001213900-26-094603-index.html | 0001213900-26-094603 |
| Document: 0001213900-26-094603.txt | 0001213900-26-094603 |
| 424B5 Filing (KZIA) — Batch item 9 | 0001213900-26-094600 |
| Document: 0001213900-26-094600-index-headers.html | 0001213900-26-094603 |
| Document: 0001213900-26-094600-index.html | 0001213900-26-094603 |
| Document: 0001213900-26-094600.txt | 0001213900-26-094603 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 25d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $8.17 (−11.87%) |
Sep 22, 2026 5w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $8.17 (−25.18%) |
Sep 1, 2026 8w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $8.17 (−35.21%) |
Aug 31, 2026 8w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $8.17 (+35.31%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $8.17 (−40.67%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $8.17 (+40.67%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $8.17 (+40.67%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $8.17 (+39.84%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $8.17 (−39.84%) |
Jul 28, 2026 13w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $8.17 (−35.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers